Published in Gene Therapy Weekly, October 19th, 2000
The vaccine is directed against prostate-specific membrane antigen (PSMA), a unique protein found on the surface of prostate cancer cells, and is designed to stimulate a patient's immune system to recognize and destroy the cancer cells. The preclinical findings were reported at the 7th Annual CaP CURE Scientific Retreat. This in vivo immunotherapy program is being conducted under a joint venture between Progenics and Cytogen.
The vaccine is a genetically-engineered,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.